PharmaBro Martin Shkreli was making enemies on Wall Street well before his drug-price hiking infamy, according to a book out this month.

In “Confessions of a Wall Street Insider,” convicted insider trader Michael Kimelman describes meeting Shkreli in late 2008. Shkreli, a 25-year-old “freakishly skinny, on-the-spectrum biotech trader” at the time, was just as brash then as when he infamously hiked up the price of Daraprim 5,000 percent to $750 per tablet in September 2015.

Shkreli was tied to Royal Bank of Canada at the time and was called in to vet the trading prowess of Franz Tudor, one of Kimelman’s colleagues at the now-closed hedge fund Incremental Capital. Despite having nearly 10 years on Shkreli, Tudor was torn apart by Shkreli’s rapid-fire questioning and “psychopathic level of statistical recall and brainpower,” Kimelman writes.

Kimelman eventually intervened to slow the blood-letting and give his colleague a break. Despite Shkreli’s seeming victory that day, his fortunes soon changed. RBC fired Shkreli months later after some of his trades cost the firm millions, Kimelman writes.

Then, of course, Shkreli was arrested and charged with securities fraud in late 2015. Kimelman predicts that if Shkreli is convicted, he will be sentenced to 10 years, he told On the Money.

Kimelman, meanwhile served nearly two years in federal prison for insider trading, and his colleague Tudor, who wore a wire to tape colleagues’ conversations, got three years probation.

Shkreli did not respond to requests for comment.